Guardant Health and Zephyr AI Partner to Advance Cancer Drug Development Through AI-Driven Insights

Guardant Health, a leader in precision oncology, has announced a strategic partnership with Zephyr AI, a precision medicine company specializing in artificial intelligence, to accelerate innovation in cancer drug development and patient care.

The collaboration aims to combine Guardant’s multimodal molecular data with Zephyr AI’s advanced machine learning platform to generate scalable, actionable insights for biopharmaceutical research, including novel biomarker discovery, targeted therapy selection, and treatment response monitoring.

The partnership will integrate with Guardant’s Infinity AI suite and reflects both companies’ shared vision of using artificial intelligence and real-world data to transform oncology research and clinical decision-making.

“At Guardant Health, we’ve always believed that data is key to conquering cancer,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “By combining our industry-leading molecular data with Zephyr AI’s analytics platform, we’re helping our biopharma partners accelerate drug development and deliver better outcomes for patients worldwide.”

The collaboration will leverage Guardant’s deep genomic and clinical datasets alongside Zephyr’s proprietary AI tools to create models capable of predicting targeted therapy responses validated by real-world data. These models will provide biologically interpretable, evidence-based insights that can guide research and clinical strategies.

“This partnership represents the convergence of unmatched real-world data, leading-edge diagnostics, and cutting-edge machine learning,” said Allen Chao, CEO of Zephyr AI. “Together, we can supercharge discovery and development to transform cancer treatment and fulfill the promise of personalized medicine.”

The alliance marks a significant step forward in the integration of AI and precision oncology, aiming to empower oncologists, researchers, and biopharma developers with data-driven tools to improve cancer outcomes.